For the Quarter Ending March 2025
North America
During Q1 2025, Amlodipine Besylate prices in the U.S. experienced fluctuating trends shaped by trade policy shifts, supply chain dynamics, and varying demand. In January, prices moderately increased as importers rushed to secure shipments ahead of the proposed 10% tariff on Chinese goods set for February. This surge in procurement, compounded by the upcoming Chinese Lunar New Year and rising energy costs, strained supply chains and elevated prices. Port congestion in Los Angeles, worsened by wildfire-related disruptions, further delayed shipments and pushed operational costs higher.
However, February saw a decline in prices due to improved Chinese production after the holiday and reduced transpacific freight rates, enhancing supply flow into the U.S. Demand weakened as economic uncertainty and prior stockpiling discouraged fresh purchases. By March, prices rose slightly amid renewed buying activity, as President Trump’s March 4 tariff actions on major trading partners reignited concerns over pharmaceutical supply disruptions. With more tariffs anticipated in April, market participants frontloaded procurement. Eased consumer inflation slightly improved sentiment, adding to the firming trend.
Overall, Q1 reflected a volatile but resilient pricing environment, driven by geopolitical and logistical factors.
Asia Pacific
In Q1 2025, the Amlodipine Besylate market in China saw notable price fluctuations driven by shifting supply and demand dynamics. In January, prices increased due to rising demand from the pharmaceutical and healthcare sectors, along with supply constraints caused by the Lunar New Year holiday, which reduced manufacturing output. Additionally, exporters rushed to frontload shipments ahead of anticipated U.S. tariffs, tightening supply and fueling bullish market sentiment. In February, prices slightly declined as supply stabilized. Manufacturing activity improved post-holiday, boosting production capacity, while demand remained weak due to deflationary pressures, limited consumer spending, and sluggish activity in the pharmaceutical sector. The impact of U.S. tariffs also led to higher domestic inventories as exporters shifted focus to local markets. By March, prices increased modestly as supply struggled to meet sustained demand. Low inventory levels, accelerated procurement from foreign buyers due to trade uncertainties, and stronger domestic demand, driven by fiscal stimulus and restocking before plant maintenance, all contributed to tightening market conditions. Overall, the quarter saw a moderate price increase, influenced by varying supply constraints and demand shifts.
Europe
In Q1 2025, Amlodipine Besylate prices in Germany saw significant fluctuations driven by a mix of demand, supply conditions, and external factors. January experienced a moderate price increase, bolstered by an improvement in German business morale and favorable monetary policy, which boosted demand from the healthcare and pharmaceutical sectors. Early stockpiling due to supply chain delays caused by the Lunar New Year further pressured prices upwards. However, February saw a price decline, as ample supply and weak demand resulted in less urgency for new orders. The appreciation of the Euro against the US Dollar and a sharp drop in freight rates allowed for cost-effective imports, leading to an inventory buildup. In contrast, March saw prices rise again as supply constraints intensified, driven by port congestion and labor unrest across Europe, affecting shipments. Restocking activity resumed, and increased confidence in the pharmaceutical sector fueled demand, leading to a price recovery. By the end of Q1, Amlodipine Besylate prices had shown a moderate upward trend, with a stronger outlook for the coming months.
For the Quarter Ending December 2024
North America
During Q4 2024, Amlodipine Besylate prices in the USA exhibited dynamic shifts, driven by evolving market conditions. Prices surged in October due to heightened demand, fueled by Federal Reserve rate cuts that bolstered consumer confidence. Prolonged port congestion, labor strikes, and fears of tariff hikes under President-elect Donald Trump disrupted supply chains, exacerbating supply-demand imbalances and driving prices upward.
In November, prices slightly declined as demand softened amidst inflationary pressures and high interest rates. The appreciation of the U.S. dollar reduced import costs, while the resolution of the ILA strike eased logistics. These factors, combined with healthy inventories, allowed suppliers to lower prices, passing on savings to consumers.
By December, Amlodipine Besylate prices fell further due to dampened consumer confidence, seasonal demand slowdowns, and proactive inventory buildup ahead of potential January strikes and the Chinese Lunar New Year. Inflation concerns and tariff uncertainties prompted cautious buying, while ample supply and competitive pricing strategies added downward pressure. Overall, Q4 showcased a volatile market that ultimately trended downward. As of the end of Q4, Amlodipine Besylate was priced at USD 72,800 per metric ton (USP, FDA) CFR Los Angeles.
Asia Pacific
In Q4 2024, the Amlodipine Besylate market in China showcased a dynamic pricing trend influenced by varying economic and market factors. In October, prices rose significantly, driven by the resurgence of China's manufacturing sector following government stimulus measures. Increased domestic and export demand, coupled with monetary easing and a depreciated yuan, bolstered consumer confidence and external orders, enabling suppliers to raise prices.
However, this upward momentum reversed in November as high inventory levels, slowing domestic demand, and weak international orders, particularly from the USA and Europe, led to oversupply and cautious market sentiment. Falling crude oil prices further reduced operational costs, prompting manufacturers to lower prices to remain competitive.
In December, prices declined further due to subdued consumer demand amid China’s ongoing disinflation. Pharmaceutical companies and international buyers adjusted procurement strategies, contributing to weaker demand. Additionally, reduced foreign orders during the holiday season left suppliers with excess stock, forcing price cuts to clear inventories before year-end. Overall, Q4 reflected a shift from price gains in October to declines in the subsequent months due to fluctuating demand and market conditions. By the end of Q4, Amlodipine Besylate was priced at USD 70800 per metric ton in China.
Europe
In Q4 2024, Amlodipine Besylate prices in Germany exhibited contrasting trends across the months. October saw a significant price increase driven by improved business morale, bolstered by optimism around economic recovery and the European Central Bank’s third interest rate cut to 3.25%. This policy spurred spending and investment, while preemptive inventory buildup and supply chain challenges, including delays at Hamburg’s ports, added upward pressure.
However, November marked a downturn as weak end-sector demand and fading inflation concerns subdued price pressures. A sharp decline in consumer spending and retail performance in Germany, coupled with a 1.9% drop in energy prices, reduced operational costs and allowed suppliers to offer competitive rates.
The downward trend persisted into December due to weak demand from key sectors, cautious buyer behavior amid inflation concerns, and increased import costs due to the euro’s depreciation. Ample inventories and year-end stock clearance efforts further weighed on prices, while harsh winter conditions slowed consumer activity and logistics, exacerbating the decline. Overall, Q4 reflected a shift from initial optimism to economic caution, impacting price dynamics. By the end of Q4, Amlodipine Besylate was priced at USD 72610 per metric ton (USP, FDA) CFR Hamburg.
For the Quarter Ending September 2024
North America
During Q3 2024, the pricing landscape for Amlodipine Besylate in North America exhibited remarkable stability, marked by consistent market conditions throughout the quarter. Several key factors contributed to this stability, including steady demand from end-users and stable supply levels, resulting in a well-balanced equilibrium between supply and demand dynamics.
In the USA, where the most significant price fluctuations occurred, market trends reflected the broader North American environment. While the quarter recorded a slight percentage decrease in prices compared to the previous quarter, this adjustment was minor and did not indicate any drastic changes. Furthermore, a comparison between the first and second halves of the quarter revealed no substantial price variance, underscoring a period characterized by relative price stability.
As Q3 2024 drew to a close, Amlodipine Besylate was priced at USD 72,985 per metric ton (USP, FDA) CFR Los Angeles. This final price underscored the market's neutral position, reflecting a period where prices remained relatively stable throughout the quarter. Such consistency reinforces the overall trend of stability in the pricing environment for this pharmaceutical product, indicating a balanced interplay of supply and demand without significant fluctuations.
Asia Pacific
In Q3 2024, the APAC region witnessed a pronounced upward trend in Amlodipine Besylate prices, influenced by several key factors. Strong global demand, particularly from major markets, led to heightened precautionary orders, driving prices higher. Compounding this were supply chain disruptions, notably exacerbated by extreme weather events, which constrained supply levels and further fueled price increases. Despite facing challenges such as geopolitical uncertainties and the impact of tariffs, the market maintained a positive sentiment, buoyed by robust demand and favorable supply dynamics. China, in particular, experienced the most significant price fluctuations, mirroring broader trends across the region. The quarter highlighted a consistent upward movement in prices, with a notable 1% increase from the first half to the second half of the quarter. By the end of Q3 2024, Amlodipine Besylate was priced at USD 70,900 per metric ton in China, emphasizing the steady growth trajectory. Market participants actively focused on inventory management strategies to navigate these evolving market conditions. Overall, the quarter showcased a resilient market for Amlodipine Besylate in the APAC region, characterized by strong demand and effective supply management amidst various challenges.
Europe
In Q3 2024, the pricing trend for Amlodipine Besylate in Europe displayed a marked increase, particularly in Germany, where the most significant price changes occurred. Several critical factors contributed to this upward movement in market prices. Firstly, sustained high demand from end-users, along with improving economic conditions and declining inflation rates, created a solid foundation for price growth. Additionally, disruptions in shipping routes, especially due to the ongoing Red Sea crisis, prompted retailers to expedite their inventory replenishment, further fueling price increases. This environment fostered a positive market sentiment, with buyers increasing their purchasing activities to secure adequate inventory levels. While there was a slight decline in prices compared to the previous quarter, the overall trend for the quarter showed a 1% increase in prices from the first half to the second half. By the end of Q3 2024, Amlodipine Besylate was priced at USD 72,725 per metric ton (USP, FDA) CFR Hamburg in Germany, underscoring the upward trajectory in pricing during this period. Overall, the quarter illustrated a robust market for Amlodipine Besylate in Europe, driven by strong demand and proactive inventory management amidst various challenges.
For the Quarter Ending June 2024
North America
In Q2 2024, the North American market for Amlodipine besylate exhibited a mixed trajectory due to a complex interplay of factors shaping the pharmaceutical landscape. The USA experienced the most significant price fluctuations, with an unstable pricing environment throughout the quarter. Prices increased in April and May but decreased in June, influenced by demand dynamics, inventory levels, and global trade activity.
Initially, prices rose due to escalating domestic demand. Consumers, undeterred by cost fatigue, showed a willingness to spend, as evidenced by stronger retail sales, which boosted demand for Amlodipine besylate. Additionally, shipping challenges in the Red Sea region necessitated longer voyages and increased sailing speeds to counter delays. These adjustments led to higher fuel costs and elevated charter rates, while operational bottlenecks further strained shipping capacity, contributing to the price hikes.
However, by the end of the quarter, prices declined due to a downturn in business sentiment, creating economic uncertainty. This lack of confidence affected the pharmaceutical and healthcare industries, resulting in subdued demand for Amlodipine besylate. The quarter concluded with Amlodipine besylate prices at USD 72,100 per metric ton CFR Los Angeles, reflecting a persistently negative pricing environment.
Asia Pacific
In Q2 2024, the pricing landscape for Amlodipine besylate in the APAC region demonstrated a mixed trajectory influenced by various factors. Initially, prices rose due to increased market confidence compared to the previous month. The manufacturing sector continued to expand, driven by a surge in both domestic and international demand, which facilitated a swift acceleration in output growth. Manufacturers responded to this heightened demand by ramping up production levels to capitalize on the influx of new orders. However, prices declined toward the end of the quarter due to an oversupply situation. Increased manufacturing capacities outpaced existing demand, leading to a surplus. Additionally, lower production costs, driven by declining raw material prices and reduced transportation expenses, allowed manufacturers to adjust their pricing strategies downward. External demand remained sluggish as key export markets faced high interest rates, impacting consumer spending on pharmaceutical products. Concluding the quarter, the price of Amlodipine Besylate (USP, FDA) FOB Shanghai stood at USD 70,000 per metric ton, reflecting a stable pricing environment amidst the fluctuating market conditions.
Europe
In Q2 2024, the pricing landscape for Amlodipine besylate in Europe demonstrated a mixed trajectory influenced by several factors. Initially, prices rose as consumer spending increased, leading to higher demand for Amlodipine besylate. This optimistic economic climate was accompanied by elevated supply chain costs, driven by rising wages and high energy prices, which pushed up the cost of goods. However, by June, prices began to decline due to sluggish consumer demand, an overstocked market, and falling freight rates. The economic downturn, combined with reduced illness occurrences associated with warmer weather, further diminished demand. The central bank's decision to maintain unchanged interest rates also added financial pressure on consumers, suppressing purchasing activity. Despite occasional disruptions in the global supply chain, such as port congestion in Asia and North Europe and adverse weather conditions, there was some relief from easing geopolitical tensions and seasonal spikes in cargo volumes. These factors collectively helped to reduce transportation costs, contributing to the further decline in prices. The quarter ended with Amlodipine Besylate (USP, FDA) CFR Hamburg in Germany priced at USD 71,780 per metric ton, reflecting a consistent downward trend throughout the quarter.
